{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"OtherAbstract": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "SpaceFlightMission": [], "KeywordList": [], "InvestigatorList": [], "PMID": "8410981", "DateCompleted": {"Year": "1993", "Month": "10", "Day": "29"}, "DateRevised": {"Year": "2019", "Month": "07", "Day": "09"}, "Article": {"Language": ["eng"], "ArticleDate": [], "ELocationID": [], "Journal": {"ISSN": "0022-2623", "JournalIssue": {"Volume": "36", "Issue": "18", "PubDate": {"Year": "1993", "Month": "Sep", "Day": "03"}}, "Title": "Journal of medicinal chemistry", "ISOAbbreviation": "J Med Chem"}, "ArticleTitle": "Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs.", "Pagination": {"StartPage": "2689", "EndPage": "2700", "MedlinePgn": "2689-700"}, "Abstract": {"AbstractText": ["A large number of camptothecin (CPT) analogs have been prepared in the 20S, 20RS, and 20R configurations with a number of ring A substituents. Topoisomerase I (T-I) inhibition data (IC50) have been obtained by standard procedures. In general, substitution at the 9 or 10 positions with amino, halogeno, or hydroxyl groups in compounds with 20S configuration results in compounds with enhanced T-I inhibition. Compounds in the 20RS configuration were less active in vitro and in vivo and those in the 20R configuration were inactive. Compounds with 10,11-methylenedioxy substitution on ring A displayed a marked increase in potency in the T-I inhibition assay. The activities of some of the analogs as determined in a variety of in vivo assays including the L-1210 mouse leukemia assay were, in general, in accord with T-I inhibition. A number of water-soluble analogs such as 20-glycinate esters, 9-glycinamides, or hydrolyzed lactone salts were prepared and tested in in vitro and in vivo assays. In general, these compounds were less active than CPT both in terms of T-I inhibition and life prolongation in the L-1210 assay. However, certain 20-glycinate esters showed good in vivo activity after iv administration."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research Triangle Institute, Research Triangle Park, North Carolina 27709."}], "LastName": "Wall", "ForeName": "M E", "Initials": "ME"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Wani", "ForeName": "M C", "Initials": "MC"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Nicholas", "ForeName": "A W", "Initials": "AW"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Manikumar", "ForeName": "G", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Tele", "ForeName": "C", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Moore", "ForeName": "L", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Truesdale", "ForeName": "A", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Leitner", "ForeName": "P", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Besterman", "ForeName": "J M", "Initials": "JM"}], "GrantList": [{"GrantID": "NCI CA-38996-01-06", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}, {"GrantID": "NCI CA50529", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Comparative Study", "Journal Article", "Research Support, Non-U.S. Gov't", "Research Support, U.S. Gov't, P.H.S."]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "J Med Chem", "NlmUniqueID": "9716531", "ISSNLinking": "0022-2623"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Topoisomerase I Inhibitors"}, {"RegistryNumber": "5MB77ICE2Q", "NameOfSubstance": "9-aminocamptothecin"}, {"RegistryNumber": "XT3Z54Z28A", "NameOfSubstance": "Camptothecin"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["chemical synthesis", "chemistry", "therapeutic use"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["analogs & derivatives", "chemical synthesis", "therapeutic use"], "DescriptorName": "Camptothecin"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Leukemia L1210"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred BALB C"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred C3H"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred DBA"}, {"QualifierName": [], "DescriptorName": "Molecular Conformation"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Stereoisomerism"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}, {"QualifierName": [], "DescriptorName": "Topoisomerase I Inhibitors"}, {"QualifierName": [], "DescriptorName": "Tumor Cells, Cultured"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "1993", "Month": "9", "Day": "3"}, {"Year": "1993", "Month": "9", "Day": "3", "Hour": "0", "Minute": "1"}, {"Year": "1993", "Month": "9", "Day": "3", "Hour": "0", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["8410981", "10.1021/jm00070a013"]}}]}